• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Antiplatelet Therapy in Patients With COVID-19-More Is Less?

作者信息

Spaetgens Bart, Nagy Magdolna, Ten Cate Hugo

机构信息

Department of Internal Medicine, Division of General Internal Medicine, Section Geriatric Medicine, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands.

Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.

出版信息

JAMA. 2022 Jan 18;327(3):223-224. doi: 10.1001/jama.2021.23866.

DOI:10.1001/jama.2021.23866
PMID:35040901
Abstract
摘要

相似文献

1
Antiplatelet Therapy in Patients With COVID-19-More Is Less?新冠病毒肺炎患者的抗血小板治疗——多即少？
JAMA. 2022 Jan 18;327(3):223-224. doi: 10.1001/jama.2021.23866.
2
COVID-19 mortality in patients on anticoagulants and antiplatelet agents.使用抗凝剂和抗血小板药物的患者的新冠病毒疾病死亡率
Br J Haematol. 2020 Aug;190(4):e192-e195. doi: 10.1111/bjh.16968. Epub 2020 Jul 19.
3
Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study.抗凝或抗血小板药物的使用与重症 COVID-19 疾病：一项倾向评分匹配的全地区研究。
Pharmacol Res. 2021 Mar;165:105473. doi: 10.1016/j.phrs.2021.105473. Epub 2021 Jan 30.
4
Heartbeat: the role of antiplatelet therapy in treatment of COVID-19 infections.心跳：抗血小板治疗在新冠病毒感染治疗中的作用
Heart. 2022 Jan;108(2):83-85. doi: 10.1136/heartjnl-2021-320691.
5
Comment on "Pre-hospital antiplatelet medication use on COVID-19 disease severity".关于“院前使用抗血小板药物对新冠病毒疾病严重程度的影响”的评论
Heart Lung. 2022 Sep-Oct;55:164-165. doi: 10.1016/j.hrtlng.2022.04.020. Epub 2022 May 2.
6
Risk and Benefit of Antiplatelet Therapy in COVID-19 Patients with Cancer and Thrombocytopenia: Letter to the Editor.抗血小板治疗对合并癌症和血小板减少症的COVID-19患者的风险与益处：致编辑的信
Cancer Invest. 2021 Mar;39(3):217-218. doi: 10.1080/07357907.2020.1871485. Epub 2021 Jan 14.
7
The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19.抗血小板药物在新型冠状病毒肺炎动脉血栓预防中的应用。
Rev Esp Cardiol (Engl Ed). 2021 Jan;74(1):114-115. doi: 10.1016/j.rec.2020.08.009. Epub 2020 Aug 28.
8
Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With COVID-19: Implications From Clinical Features to Pathologic Findings.2019冠状病毒病患者经皮冠状动脉介入治疗后的抗血小板治疗：从临床特征到病理发现的启示
Circulation. 2020 Jun 2;141(22):1736-1738. doi: 10.1161/CIRCULATIONAHA.120.046988. Epub 2020 Apr 16.
9
Early de-escalation of DAPT after PCI: implications of the latest randomized trials in the COVID era.PCI术后双联抗血小板治疗的早期降阶梯：COVID时代最新随机试验的意义
Indian Heart J. 2020 May-Jun;72(3):209-211. doi: 10.1016/j.ihj.2020.05.009. Epub 2020 May 23.
10
Unusual arterial thrombotic events in Covid-19 patients.新冠病毒感染患者的不常见动脉血栓栓塞事件。
Int J Cardiol. 2021 Jan 15;323:281-284. doi: 10.1016/j.ijcard.2020.08.103. Epub 2020 Sep 10.

引用本文的文献

1
The effect of current antithrombotic therapy on mortality in nursing home residents with COVID-19: a multicentre retrospective cohort study.当前抗血栓治疗对 COVID-19 养老院居民死亡率的影响：一项多中心回顾性队列研究。
Age Ageing. 2024 May 1;53(5). doi: 10.1093/ageing/afae094.
2
Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.我们在新冠疫情时代过去四年充满挑战的岁月中学到的经验教训：药物治疗、新冠长期并发症和疫苗研发。
Virol J. 2024 Apr 26;21(1):98. doi: 10.1186/s12985-024-02370-6.
3
Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China.
中国上海针对新型冠状病毒肺炎重症和危重症患者结局的综合干预措施
Microorganisms. 2023 Jul 23;11(7):1859. doi: 10.3390/microorganisms11071859.
4
Pathophysiological mechanisms of thrombosis in acute and long COVID-19.急性 COVID-19 和长新冠中的血栓形成的病理生理学机制。
Front Immunol. 2022 Nov 16;13:992384. doi: 10.3389/fimmu.2022.992384. eCollection 2022.
5
Platelets in COVID-19 disease: friend, foe, or both?新型冠状病毒疾病中的血小板：朋友、敌人，还是两者皆有？
Pharmacol Rep. 2022 Dec;74(6):1182-1197. doi: 10.1007/s43440-022-00438-0. Epub 2022 Dec 3.
6
The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.缺血再灌注损伤在类风湿性关节炎、长新冠和 ME/CFS 等慢性、复发性疾病中的潜在作用：证据、机制和治疗意义。
Biochem J. 2022 Aug 31;479(16):1653-1708. doi: 10.1042/BCJ20220154.
7
Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?血小板-白细胞相互作用与 COVID-19：血栓事件和炎症状态之间的相互联系如何影响治疗策略和疾病预后？
Thromb Res. 2022 May;213:179-194. doi: 10.1016/j.thromres.2022.03.022. Epub 2022 Mar 31.
8
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.抗血小板治疗对COVID-19重症患者生存及无器官支持天数的影响：一项随机临床试验
JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910.
9
Shining a light on platelet activation in COVID-19.揭示新冠病毒肺炎中的血小板激活情况。
J Thromb Haemost. 2022 Jun;20(6):1286-1289. doi: 10.1111/jth.15678. Epub 2022 Mar 2.